Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Lupus ; 27(12): 1953-1959, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30205743

RESUMO

Background and objective Pneumonia remains the main cause of mortality in patients with systemic lupus erythematosus (SLE). The aim of the study was to establish the clinical characteristics, microbiology and risk factors for poor prognosis in patients with SLE and pneumonia. Methods We reviewed medical records of patients with SLE (American College of Rheumatology criteria) and pneumonia who attended the emergency room in a single tertiary care center (January 2010-March 2015). We collected demographics, treatment and disease activity (SLEDAI-2K) data. Severity scales of pneumonia (CURB-65 (acronym for risk factors measured: confusion, urea nitrogen, respiratory rate, blood pressure, 65 years of age and older) and Pneumonia Severity Index (PSI)) were obtained. A negative composite outcome was defined as need for mechanical ventilation, septic shock or death secondary to pneumonia up to 30 days after discharge. We conducted a univariate and multivariable analysis. Results We studied 158 patients (76% women) with 187 episodes of pneumonia. There were no differences in age, SLE duration, SLE activity, treatment or comorbidities between patients with negative composite outcome vs the other group. In 53 episodes, patients presented with a negative composite outcome. Of these, 46 (24.6%) required intubation, 13 (7%) developed shock and 12 (6.4%) died. The most common bacteria isolated was S. aureus, and we observed a high percentage of nonhabitual microorganisms. Fifteen percent of patients who presented with a negative outcome had low values on CURB-65 and PSI scales. Conclusion Patients with SLE and pneumonia have a high risk of complications and present with a high percentage of nonhabitual microorganisms. Severity scales for pneumonia can misclassify as low risk SLE patients with poor prognosis.


Assuntos
Lúpus Eritematoso Sistêmico/complicações , Pneumonia/mortalidade , Staphylococcus aureus/isolamento & purificação , Adulto , Serviço Hospitalar de Emergência , Feminino , Humanos , Modelos Logísticos , Lúpus Eritematoso Sistêmico/microbiologia , Masculino , México , Análise Multivariada , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Centros de Atenção Terciária , Adulto Jovem
2.
Lupus ; 15(9): 600-5, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17080916

RESUMO

CD55 and CD59 are glycophosphatidylinositol-anchored proteins with complement inhibitory properties. Lymphopenia in systemic lupus erythematosus (SLE) has been associated with autoantibodies targeting nuclear antigens. The aim of this study was to evaluate the surface density of CD55 and CD59 in T and B lymphocytes from patients with SLE and lymphopenia and its possible correlation with the presence of common SLE autoantibodies. Flow cytometric analyses were performed on CD55 and CD59 stained CD3+ and CD19+ cells from 40 SLE patients, 30 with lymphopenia and 10 without it, and 25 healthy controls. Autoantibodies were detected in the sera by enzyme linked immunosorbent assay. The mean fluorescence intensity of CD55 and CD59 in T and B cells was significantly diminished in SLE patients with lymphopenia when compared with healthy subjects. Interestingly, the opposite was found in T and B cells from non-lymphopenic SLE patients. Although there was no correlation between CD55 and CD59 surface density and the presence of any specificity of the autoantibodies tested, higher titres of anti-dsDNA, anti-SM and anti-ribosomal p antibodies were significantly associated with lymphopenia. The deficiency of CD55 and CD59 expression may play a role in the pathophysiology of lymphopenia, most likely by increasing the susceptibility of cells to complement mediated cytolysis.


Assuntos
Linfócitos B/metabolismo , Antígenos CD55/biossíntese , Antígenos CD59/biossíntese , Lúpus Eritematoso Sistêmico/metabolismo , Linfopenia/metabolismo , Linfócitos T/metabolismo , Adulto , Anticorpos Antinucleares/metabolismo , Antígenos CD19/metabolismo , Complexo CD3/metabolismo , Estudos de Casos e Controles , Regulação para Baixo , Ensaio de Imunoadsorção Enzimática , Feminino , Citometria de Fluxo , Humanos , Masculino , Pessoa de Meia-Idade , Testes Sorológicos
3.
Eur J Haematol ; 71(3): 224-30, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12930326

RESUMO

Atypical chronic lymphocytic leukemia (CLL) expressing the CD8 antigen have a frequency of less than 0.5% of all cases, however, they are not yet been fully characterized. Herein a CD8+ CLL case was extensively studied. Besides the classical CLL antigen expression, an unusual presence of surface markers such as CD11c, CD56, and CD154 was observed. Moreover, gene expression of chemokine receptors belonging to the CCR family were clearly evidenced as well as mRNA for both, Th1 and Th2 cytokines. Likewise, granzyme A, B and perforin gene expression, cytotoxic T cell or NK enzymes were found. The intricate profile of membrane molecules and gene expression suggest that it could be favorable, rather than deletereous, for the maintainance of the neoplastic process.


Assuntos
Antígenos CD8/análise , Leucemia Linfocítica Crônica de Células B/imunologia , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/análise , Antígeno CD11c/análise , Ligante de CD40/análise , Antígeno CD56/análise , Citocinas/genética , Feminino , Humanos , Imunofenotipagem , Interleucinas/genética , Pessoa de Meia-Idade , RNA Mensageiro/análise , Receptores de Quimiocinas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA